HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TVTX
Travere Therapeutics, Inc.
TVTX lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TVTX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Healthy | |
| Strong |
TVTX's revenue, cash flow and balance sheet are currently healthy, but its profitability is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TVTX PE Valuation
TVTX has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 18x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TVTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
TVTX has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TVTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.94 | — |
| Q3 2026 | -$1.28 | -$0.24 |
| Q2 2026 | -$0.45 | +$1.57 |
| Q1 2026 | -$0.22 | +$2.57 |
| Q4 2025 | -$0.29 | +$3.79 |
| Q3 2025 | -$1.04 | +$3.51 |
| Q2 2025 | -$2.02 | -$0.14 |
| Q1 2025 | -$2.79 | -$0.69 |
| Q4 2024 | -$4.08 | -$2.47 |
TVTX is still losing money, but far less than before: $1.28 per share over the past year, against $4.56 at its worst in late 2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over TVTX on profitability, with a higher operating margin.
TVTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $224.6M | +36% |
| Q2 2026 | $169.6M | +48% |
| Q1 2026 | $127.2M | +56% |
| Q4 2025 | $129.7M | +73% |
| Q3 2025 | $164.9M | +162% |
| Q2 2025 | $114.4M | +111% |
| Q1 2025 | $81.7M | +98% |
| Q4 2024 | $74.8M | +66% |
TVTX has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | -45 points |
| Q2 2026 | 2.3% | +13 points |
| Q1 2026 | -29% | +23 points |
| Q4 2025 | -25% | +56 points |
| Q3 2025 | 15% | +104 points |
| Q2 2025 | -11% | +114 points |
| Q1 2025 | -52% | +284 points |
| Q4 2024 | -81% | +128 points |
TVTX's operating margin was −30% last quarter, down 45 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
TVTX has the stronger cash trend. Its trailing FCF is up 168% versus its history, compared with HIMS at down 84%.
TVTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$40.4M | +$1.8M |
| Q4 2025 | $60.7M | +$96.4M |
| Q3 2025 | $14.2M | +$56.7M |
| Q1 2025 | -$42.2M | +$76.8M |
| Q4 2024 | -$35.7M | +$34.8M |
| Q2 2024 | -$40.3M | +$29M |
| Q1 2024 | -$119M | -$37.3M |
| Q4 2023 | -$70.5M | -$15.8M |
TVTX's free cash flow has turned positive after five years mostly in the red: $93M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TVTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.1M shares |
| 1 year | -7.8% | -8M shares |
| 3 years | +24% | +18.3M shares |
| 5 years | +56% | +33.8M shares |
| Available history | +123% | +52.3M shares |
TVTX has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over TVTX on leverage, with a lower net debt burden relative to earnings.
TVTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -5.1x | Net Cash |
| Q1 2026 | -4.9x | Net Cash |
TVTX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TVTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.4 | Neutral |
| Stochastic | 18.2 | Oversold |
TVTX's weekly RSI is 48 (neutral) and its Stochastic is 18 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TVTX PE vs Healthcare Sector
TVTX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TVTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.5 | 1.7% below |
| 20 week MA | $57.6 | 11% below |
| 50 week MA | $45.2 | 14% above |
| 100 week MA | $32.9 | 57% above |
| 200 week MA | $22.8 | 126% above |
TVTX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TVTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.4 | $27.6 | +92% |
| 2021 | $27.6 | $31.2 | +13% |
| 2022 | $31.2 | $20.0 | -36% |
| 2023 | $20.0 | $8.99 | -55% |
| 2024 | $8.99 | $17.3 | +92% |
| 2025 | $17.3 | $39.6 | +129% |
| 2026 YTD | $39.6 | $51.6 | +30% |
TVTX has the edge over HIMS on returns for 2026, with the stronger performance.